VivoSeq
Oncology

Adenocarcinoma, Pancreatic Ductal

3

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Adenocarcinoma, Pancreatic Ductal is an early-stage landscape with 3 programs across 2 companies. The most active players are Roche, Incyte.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 2Incyte logo

Incyte

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

Autogene Cevumeran

Roche

Atezolizumab

Roche

Mfolfirinox

Incyte

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Monoclonal antibody150%

Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
Recruiting·Roche logoRoche·Phase 2·NCT05968326·260 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)